Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Belinostat + 5-fluorouracil is an experimental combination therapy for cancer, specifically investigated in renal cell carcinoma and T-cell lymphomas. This regimen combines belinostat, a pan-histone deacetylase (HDAC) inhibitor, with 5-fluorouracil (5-FU), a pyrimidine analog antimetabolite that interferes with DNA synthesis. The combination synergistically induces apoptosis and DNA damage in cancer cells through increased caspase activation, ROS-mediated injury, and attenuation of thymidylate synthase induction (via HSP90 hyperacetylation), enhancing the anticancer effects of 5-FU. This treatment has demonstrated reduction of tumor volume and prolonged progression-free survival in preclinical and early clinical studies in renal cell carcinoma and some T-cell lymphoma patients[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on belinostat + 5-fluorouracil.